(Q44261960)

English

Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: a randomized, open-label, multicenter study of clinical

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

1 December 2017

Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: a randomized, open-label, multicenter study of clinical (English)

1 reference

Europe PubMed Central

1 December 2017

0 references

hospitalization

1 reference

based on heuristic

inferred from title

2

object named as

Thomas M File

1 reference

Europe PubMed Central

1 December 2017

author name string

Hartmut Lode

1

1 reference

Europe PubMed Central

1 December 2017

Lionel Mandell

3

1 reference

Europe PubMed Central

1 December 2017

Peter Ball

4

1 reference

Europe PubMed Central

1 December 2017

Rienk Pypstra

5

1 reference

Europe PubMed Central

1 December 2017

Michael Thomas

6

1 reference

Europe PubMed Central

1 December 2017

185 Gemifloxacin Study Group

7

1 reference

Europe PubMed Central

1 December 2017

publication date

1 November 2002

1 reference

Europe PubMed Central

1 December 2017

Clinical Therapeutics

1 reference

Europe PubMed Central

1 December 2017

24

1 reference

Europe PubMed Central

1 December 2017

11

1 reference

Europe PubMed Central

1 December 2017

1915-1936

1 reference

Europe PubMed Central

1 December 2017

Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980088-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980088-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance Study in Ohio. The Community-Based Pneumonia Incidence Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980088-1

7 January 2021

based on heuristic

inferred from DOI database lookup

A prediction rule to identify low-risk patients with community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980088-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Early Switch From Intravenous to Oral Antibiotics and Early Hospital Discharge

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980088-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Sequential therapy in the hospital management of lower respiratory infections

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980088-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Purification of pneumococcal type II topoisomerases and inhibition by gemifloxacin and other quinolones

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980088-1

7 January 2021

based on heuristic

inferred from DOI database lookup

A comparative In vitro surveillance study of gemifloxacin activities against 2,632 recent Streptococcus pneumoniae isolates from across Europe, North America, and South America. The Gemifloxacin Surveillance Study Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980088-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980088-1

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro activity of gemifloxacin against a broad range of recent clinical isolates from the USA

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980088-1

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro activities of gemifloxacin (SB 265805, LB20304) against recent clinical isolates of Chlamydia pneumoniae.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980088-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative potency of gemifloxacin, new quinolones, macrolides, tetracycline and clindamycin against Mycoplasma spp

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980088-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative in vitro activity and post-antibiotic effect of gemifloxacin against Legionella spp.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980088-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980088-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of gemifloxacin 320 mg once-daily for 7 days in the treatment of adult lower respiratory tract infections

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980088-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacoeconomic benefit of antibiotic step-down therapy: converting patients from intravenous ceftriaxone to oral cefpodoxime proxetil

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980088-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian Community-Acquired Pneumonia Working Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980088-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980088-1

7 January 2021

based on heuristic

inferred from DOI database lookup

A multicenter study of grepafloxacin and clarithromycin in the treatment of patients with community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980088-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized, double-blind, comparative study of grepafloxacin and amoxycillin in the treatment of patients with community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980088-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Cost-effectiveness of gatifloxacin vs ceftriaxone with a macrolide for the treatment of community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980088-1

7 January 2021

based on heuristic

inferred from DOI database lookup

[Oral levofloxacin versus intravenous ceftriaxone and amoxicillin/clavulanic acid in the treatment of community-acquired pneumonia that requires hospitalization]

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980088-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The use of oral temafloxacin compared with a parenteral cephalosporin in hospitalized patients with pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980088-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Oral ofloxacin for the treatment of acute bacterial pneumonia: use of a nontraditional protocol to compare experimental therapy with "usual care" in a multicenter clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980088-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The hidden impact of antibacterial resistance in respiratory tract infection. Clinical failures: the tip of the iceberg?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980088-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Infectious Complications with Respiratory Pathogens despite Ciprofloxacin Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980088-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical effectiveness of levofloxacin in patients with acute purulent exacerbations of chronic bronchitis: the relationship with in-vitro activity.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980088-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980088-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980088-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Fluoroquinolone toxicity profiles: a review focusing on newer agents

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980088-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980088-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of cefadroxil and cephalexin in the treatment of community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980088-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The effect of intravenous-to-oral switch guidelines on the use of parenteral antimicrobials in medical wards

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980088-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980088-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0149-2918(02)80088-1

1 reference

Europe PubMed Central

1 December 2017

1 reference

Europe PubMed Central

1 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44261960&oldid=2108974684"